Given the role of EGFR, ErbB2 and FAK signaling pathways in CD151-mediated NSCLC carcinogenesis, vector or CD151 transfected A549 and H1299 cells were treated with Gefitinib (EGFR-TKI inhibitor), Lapatinib (ErbB2 inhibitor) and VS6063 (FAK inhibitor) separately. The gene discussed is PTK2; the disease is non-small cell lung carcinoma.